Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature - 08/12/17
, Umar Wazir, Kinan Mokbel, Abdul Kasem, Kefah MokbelAbstract |
Introduction |
Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid in the therapeutic decision-making.
Methods |
We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer.
Results and conclusions |
Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy.
El texto completo de este artículo está disponible en PDF.Highlights |
• | Breast cancer is a heterogeneous disease based on variations in molecular characteristics. |
• | Online prognostication tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. |
• | Molecular profiling appears to be superior in predicting clinical outcome and guiding therapy. |
Keywords : Breast cancer, Prognosis, Genetic testing, Genomics, Adjuvant
Esquema
Vol 215 - N° 1
P. 171-178 - janvier 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
